NO872541L - Fremgangsmte ved fremstilling av immunomodulatorer. - Google Patents
Fremgangsmte ved fremstilling av immunomodulatorer.Info
- Publication number
- NO872541L NO872541L NO872541A NO872541A NO872541L NO 872541 L NO872541 L NO 872541L NO 872541 A NO872541 A NO 872541A NO 872541 A NO872541 A NO 872541A NO 872541 L NO872541 L NO 872541L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- hiv
- transfer factor
- animal
- specific transfer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000002955 immunomodulating agent Substances 0.000 title description 2
- 229940121354 immunomodulator Drugs 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 66
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 208000030507 AIDS Diseases 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 14
- 230000003053 immunization Effects 0.000 claims abstract description 11
- 210000005229 liver cell Anatomy 0.000 claims abstract description 10
- 238000002649 immunization Methods 0.000 claims abstract description 9
- 108010074506 Transfer Factor Proteins 0.000 claims description 56
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 42
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 210000000952 spleen Anatomy 0.000 claims description 8
- 230000001195 anabolic effect Effects 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229940124325 anabolic agent Drugs 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 40
- 241001430294 unidentified retrovirus Species 0.000 description 22
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 208000008771 Lymphadenopathy Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 8
- 208000018555 lymphatic system disease Diseases 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000000207 lymphocyte subset Anatomy 0.000 description 5
- 206010001513 AIDS related complex Diseases 0.000 description 4
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 230000000652 homosexual effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002512 suppressor factor Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- PGAUJQOPTMSERF-QWQRBHLCSA-N Methenolone acetate Chemical compound C([C@@H]1CC2)C(=O)C=C(C)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)C)[C@@]2(C)CC1 PGAUJQOPTMSERF-QWQRBHLCSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000013228 adenopathy Diseases 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229960005270 methenolone acetate Drugs 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000002976 reverse transcriptase assay Methods 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- UVBCRFAFWVSXOL-JGVFFNPUSA-N 3-azido-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N(N=[N+]=[N-])C(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 UVBCRFAFWVSXOL-JGVFFNPUSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000714195 Aids-associated retrovirus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- -1 indome-tasin Chemical compound 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PBJNZCQJMWVIRT-MDQYBHOLSA-N inosine pranobex Chemical compound CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C2=NC=NC(O)=C2N=C1 PBJNZCQJMWVIRT-MDQYBHOLSA-N 0.000 description 1
- 229960000476 inosine pranobex Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868614733A GB8614733D0 (en) | 1986-06-17 | 1986-06-17 | Aids treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO872541D0 NO872541D0 (no) | 1987-06-17 |
| NO872541L true NO872541L (no) | 1987-12-18 |
Family
ID=10599595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO872541A NO872541L (no) | 1986-06-17 | 1987-06-17 | Fremgangsmte ved fremstilling av immunomodulatorer. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0250234A1 (fr) |
| JP (1) | JPS6360932A (fr) |
| AU (1) | AU7441587A (fr) |
| CH (1) | CH673396A5 (fr) |
| DE (1) | DE3720434A1 (fr) |
| DK (1) | DK308687A (fr) |
| FR (1) | FR2599971B1 (fr) |
| GB (2) | GB8614733D0 (fr) |
| IL (1) | IL82893A0 (fr) |
| NO (1) | NO872541L (fr) |
| PT (1) | PT85115A (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284664A (en) * | 1988-08-04 | 1994-02-08 | Kremers-Urban Company | Method of treating the symptoms of Alzheimer's disease |
| US5055296A (en) * | 1988-08-04 | 1991-10-08 | Wagle Sudhakar S | Method of treating chronic fatigue syndrome |
| US5334395A (en) * | 1988-08-04 | 1994-08-02 | Kremers-Urban Company | Method of treating an epstein-barr viral infection |
| DE3827490A1 (de) * | 1988-08-12 | 1990-02-15 | Hor Fer Vit Pharma Gmbh | Herrichtung und verwendung eines physiologisch aktiven polypeptids zur aids-therapie |
| EP0537722A3 (en) * | 1991-10-15 | 1994-07-13 | Kremers Urban Co | Porcane liver polypeptides for treating viral infections |
| WO2004041071A2 (fr) * | 2002-11-04 | 2004-05-21 | 4Life Research, Lc | Compositions, systemes et methodes permettant de focaliser une reponse immunitaire a mediation cellulaire |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2073293B1 (fr) * | 1969-12-31 | 1973-01-12 | Pasteur Institut | |
| US3991182A (en) * | 1971-10-19 | 1976-11-09 | The Regents Of The University Of California | Transfer factor |
| GB1443948A (en) * | 1972-10-20 | 1976-07-28 | Piktor Ltd | Production of immunological material |
| GB1592954A (en) * | 1976-12-16 | 1981-07-15 | Int Inst Of Differentiation | Cell line |
| US4132776A (en) * | 1978-02-15 | 1979-01-02 | University Patents, Inc. | Delivery of immunologically active components of transfer factor |
| US4180627A (en) * | 1978-08-17 | 1979-12-25 | The United States Of America As Represented By The Secretary Of Agriculture | Process for in vivo transfer of cell-mediated immunity in mammals with alcoholic precipitates of Bovine Transfer factor |
| WO1980000790A1 (fr) * | 1978-10-25 | 1980-05-01 | Benzon As Alfred | Facteur de transfert et procede de preparation |
| IE53572B1 (en) * | 1980-05-14 | 1988-12-21 | Arthur Gottlieb A | Modulators of the immune system |
| US4323555A (en) * | 1980-11-03 | 1982-04-06 | The Regents Of The University Of California | Method of protecting cattle and sheep against bovine leukemia virus and vaccines for use therein |
| US4468379A (en) * | 1982-05-06 | 1984-08-28 | Endeavor Corp. | Leukocyte extracts for affecting the immune system |
| JPS5967226A (ja) * | 1982-07-20 | 1984-04-16 | デイミトリ・ビザ | ウイルス感染処置に使用する転移因子 |
| US4521407A (en) * | 1983-08-29 | 1985-06-04 | Serono Pharmaceutical Partners | Treatment of acquired immune deficiency syndrome with thymus extract |
| GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
-
1986
- 1986-06-17 GB GB868614733A patent/GB8614733D0/en active Pending
-
1987
- 1987-06-16 IL IL82893A patent/IL82893A0/xx unknown
- 1987-06-17 DK DK308687A patent/DK308687A/da not_active Application Discontinuation
- 1987-06-17 AU AU74415/87A patent/AU7441587A/en not_active Abandoned
- 1987-06-17 JP JP62151048A patent/JPS6360932A/ja active Pending
- 1987-06-17 FR FR878708484A patent/FR2599971B1/fr not_active Expired - Fee Related
- 1987-06-17 CH CH2289/87A patent/CH673396A5/fr not_active IP Right Cessation
- 1987-06-17 NO NO872541A patent/NO872541L/no unknown
- 1987-06-17 PT PT85115A patent/PT85115A/pt unknown
- 1987-06-17 GB GB08714181A patent/GB2193498A/en not_active Withdrawn
- 1987-06-17 EP EP87305389A patent/EP0250234A1/fr not_active Withdrawn
- 1987-06-19 DE DE19873720434 patent/DE3720434A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PT85115A (en) | 1987-07-01 |
| GB8614733D0 (en) | 1986-07-23 |
| DK308687D0 (da) | 1987-06-17 |
| CH673396A5 (fr) | 1990-03-15 |
| AU7441587A (en) | 1987-12-24 |
| GB2193498A (en) | 1988-02-10 |
| DE3720434A1 (de) | 1987-12-23 |
| GB8714181D0 (en) | 1987-07-22 |
| EP0250234A1 (fr) | 1987-12-23 |
| NO872541D0 (no) | 1987-06-17 |
| FR2599971B1 (fr) | 1990-11-30 |
| IL82893A0 (en) | 1987-12-20 |
| DK308687A (da) | 1987-12-18 |
| FR2599971A1 (fr) | 1987-12-18 |
| JPS6360932A (ja) | 1988-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bender et al. | Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro | |
| Nakashima et al. | Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae | |
| Jackson et al. | Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS | |
| DE69535035T2 (de) | Präparate zur verabreichung von genetischem material | |
| Bagby et al. | The effect of chronic binge ethanol consumption on the primary stage of SIV infection in rhesus macaques | |
| Wood et al. | Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study | |
| CA2006119C (fr) | Agents contre le virus du sida ayant une action anticancereuse | |
| Crowe | Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection | |
| NO872541L (no) | Fremgangsmte ved fremstilling av immunomodulatorer. | |
| KR19990044834A (ko) | 네가티브인자작용 억제제 | |
| JP2001505583A (ja) | 抗ウイルス活性を有するサルビア種の抽出物 | |
| LUDEWIG et al. | Transmission of HIV-1 from productively infected mature Langerhans cells to primary CD4+ T lymphocytes results in altered T cell responses with enhanced production of IFN-γ and IL-10 | |
| US10336817B2 (en) | Therapeutic composition of camel milk | |
| AU641002B2 (en) | Method of treatment of retrovirus infections | |
| JP2004506015A (ja) | レトロウイルス免疫療法 | |
| PORWIT et al. | Cell association of HIV in AIDS‐related encephalopathy and dementia | |
| JPH01120284A (ja) | Ｈｉｖ不完全粒子および該製造方法 | |
| EP0295962B1 (fr) | Polysaccharide protéinique pour le traitement des infections réovirales | |
| Zeidner et al. | Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′, 3′-dideoxycytidine | |
| JP4121957B2 (ja) | 藍調製物、ならびにそのヒト免疫不全ウイルスの感染予防または治療における用途 | |
| WO1989009229A1 (fr) | Traitement de patient atteint de viremie du hiv a l'aide de thymopentine | |
| CN101347492A (zh) | 一种剑叶三宝木提取物在制备抗艾滋病病毒药物中的应用 | |
| Gupta et al. | Treatment of the acquired immune deficiency syndrome | |
| Wong et al. | Immunologic reconstitution in a patient with keratoconjunctivitis, superficial candidiasis and hypoparathyroidism: the role of immunocompetent lymphocyte transfusion and transfer factor. | |
| Lyons et al. | Search for a retroviral cause for sarcoidosis: no evidence from peripheral blood studies |